GT
LKFT

Glenmede Trust’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Glenmede Trust’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-65
Closed -$9K – 1627
2020
Q3 		$9K Sell
65
-2
-3% -$333 ﹤0.01% 1914
2020
Q2 		$13K Buy
67
+59
+738% +$12.2K ﹤0.01% 1768
2020
Q1 		$1K Hold
8
– – ﹤0.01% 2929
2019
Q4 		$1K Hold
8
– – ﹤0.01% 2929
2019
Q3 		$1 Sell
8
-7
-47% -$1.15K ﹤0.01% 2924
2019
Q2 		$1 Hold
15
– – ﹤0.01% 2962
2019
Q1 		$1 Hold
15
– – ﹤0.01% 2930
2018
Q4 		$1 Buy
+15
New +$1.52K ﹤0.01% 2882

Other funds holding LKFT

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Glenmede Trust's LKFT Position: Q4 2020 in Review

Glenmede Trust sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2020, closing a stake of 65 shares — an estimated $9K sold.

Glenmede Trust first reported a position in LKFT in Q4 2018 and held it in 8 quarters. The position peaked at $13K in Q2 2020. 116 funds tracked by Wall St. Rank hold LKFT as of Q4 2020.

  • Glenmede Trust reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 65 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2020, an estimated $9K.
  • Glenmede Trust first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2018 and held it in 8 quarters.
  • Glenmede Trust's Lakefront Biotherapeutics American Depositary Shares position peaked at $13K in Q2 2020.
  • 116 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.